Vanda Pharmaceuticals (VNDA) Receivables (2016 - 2025)
Historic Receivables for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to $54.6 million.
- Vanda Pharmaceuticals' Receivables rose 1587.44% to $54.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $54.6 million, marking a year-over-year increase of 1587.44%. This contributed to the annual value of $54.6 million for FY2025, which is 1587.44% up from last year.
- As of Q4 2025, Vanda Pharmaceuticals' Receivables stood at $54.6 million, which was up 1587.44% from $50.5 million recorded in Q3 2025.
- In the past 5 years, Vanda Pharmaceuticals' Receivables registered a high of $54.6 million during Q4 2025, and its lowest value of $24.5 million during Q1 2023.
- For the 5-year period, Vanda Pharmaceuticals' Receivables averaged around $37.5 million, with its median value being $35.4 million (2023).
- In the last 5 years, Vanda Pharmaceuticals' Receivables soared by 5085.21% in 2021 and then crashed by 2926.55% in 2022.
- Over the past 5 years, Vanda Pharmaceuticals' Receivables (Quarter) stood at $32.5 million in 2021, then rose by 3.22% to $33.5 million in 2022, then grew by 1.92% to $34.2 million in 2023, then soared by 37.9% to $47.1 million in 2024, then increased by 15.87% to $54.6 million in 2025.
- Its Receivables was $54.6 million in Q4 2025, compared to $50.5 million in Q3 2025 and $45.0 million in Q2 2025.